An Update on the Therapeutic Potential of Antimicrobial Peptides against Acinetobacter baumannii Infections

Author:

Rangel Karyne12,Lechuga Guilherme Curty12,Provance David W.12,Morel Carlos M.1ORCID,De Simone Salvatore G.1234ORCID

Affiliation:

1. Center for Technological Development in Health (CDTS), National Institute of Science and Technology for Innovation in Neglected Population Diseases (INCT-IDPN), Oswaldo Cruz Institut, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil

2. Epidemiology and Molecular Systematics Laboratory (LEMS), Oswaldo Cruz Institut, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil

3. Program of Post-Graduation on Science and Biotechnology, Department of Molecular and Cellular Biology, Biology Institute, Federal Fluminense University, Niterói 22040-036, RJ, Brazil

4. Program of Post-Graduation on Parasitic Biology, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro 21040-900, RJ, Brazil

Abstract

The rise in antibiotic-resistant strains of clinically important pathogens is a major threat to global health. The World Health Organization (WHO) has recognized the urgent need to develop alternative treatments to address the growing list of priority pathogens. Antimicrobial peptides (AMPs) rank among the suggested options with proven activity and high potential to be developed into effective drugs. Many AMPs are naturally produced by living organisms protecting the host against pathogens as a part of their innate immunity. Mechanisms associated with AMP actions include cell membrane disruption, cell wall weakening, protein synthesis inhibition, and interference in nucleic acid dynamics, inducing apoptosis and necrosis. Acinetobacter baumannii is a critical pathogen, as severe clinical implications have developed from isolates resistant to current antibiotic treatments and conventional control procedures, such as UV light, disinfectants, and drying. Here, we review the natural AMPs representing primary candidates for new anti-A. baumannii drugs in post-antibiotic-era and present computational tools to develop the next generation of AMPs with greater microbicidal activity and reduced toxicity.

Funder

Carlos Chagas Filho Foundation for Research Support of the State of Rio de Janeiro/FAPERJ

Brazilian Council for Scientific Research

National Institutes of Science and Technology Program

Publisher

MDPI AG

Subject

Drug Discovery,Pharmaceutical Science,Molecular Medicine

Reference323 articles.

1. O’Neill, J. (2016). Tackling Drug-Resistance Infections Globally: Final Report and Recommendations, The Review on Antimicrobial Resistance; Government of the United Kingdom.

2. Discovery, research, and development of new. antibiotics: The WHO priority list of antibiotic-resistant bacteria and tuberculosis;Tacconelli;Lancet Infect. Dis.,2018

3. Persister cells, dormancy, and infectious disease;Lewis;Nat. Rev. Microbiol.,2007

4. Persistent bacterial infections and persister cells;Fisher;Nat. Rev. Microbiol.,2017

5. Keen, P., and Monforts, M. (2011). Antimicrobial Resistance in the Environment, Wiley-Blackwell.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3